-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 20, Ruijian Pharmaceutical, a high-tech pharmaceutical company focused on the regeneration of functional cells induced by high-efficiency chemical small molecules, announced the completion of nearly 100 million yuan in A+ round of financing.
The funds raised will be mainly used to promote the company's research pipeline for Parkinson's disease- - NouvNeu001 is carrying out the first phase of clinical work, and at the same time supports the company's follow-up pipeline - NS001 in the Sino-US new drug clinical research (IND) dual application
.
On the same day, Aiwei Pharmaceutical, an innovative biotechnology company focusing on the field of ophthalmic treatment, announced the completion of US$25 million in Series A+ financing.
The company plans to use the investment funds to complete the global Phase II trial of the first-line treatment drug IVIEW-1201 for viral conjunctivitis , and advance the company's preclinical programs, including new class I and class II drugs for the treatment of dry eye and cataracts, into clinical development
.
Recently, Sihuan Pharmaceutical also announced that its holding subsidiary Xuanzhu Bio has completed over 600 million yuan in Series B financing
.
Xuanzhu Bio is an innovative drug subsidiary of Sihuan Pharmaceutical, a large domestic pharmaceutical and medical beauty group.
It has the ability to independently develop innovative drugs, and has formed a complete R&D system.
It has complete drug development and industrialization capabilities, and does not rely on license in And CRO, with the ability to continue innovation and continuous output
.
Innovative biopharmaceutical companies are ushering in a capital feast
.
According to statistics from Southwest Securities, in the first half of this year, innovative drugs completed 4 large financing events of over 1 billion yuan; and 8 large financing events of over 500 million yuan, accounting for 5.
9%
.
In addition, there were 45 large-amount financing events exceeding 100 million yuan in the first half of the year, accounting for 33.
3%
.
In the financing event of more than 1 billion yuan, the domestic mRNA new drug research and development company Siwei has completed a financing amount of more than 1 billion yuan
.
From the perspective of the general background, with the advancement of the pharmaceutical reform, the pharmaceutical industry has accelerated into a new era of innovation.
Based on the complete domestic innovative drug industry chain, huge domestic demand market and huge space for overseas exports, the market prospect of innovative pharmaceutical companies is very broad.
.
In this context, capital is paying more and more attention to biomedicine, making the industry's IPO financing activities more active
.
With the help of capital, China's innovative pharmaceutical companies have also opened a new stage of development
.
In particular, the launch of the Science and Technology Innovation Board has greatly improved the inclusiveness and adaptability of technologically innovative companies, promoted new discovery of value in the pharmaceutical industry, and ushered in the intensive listing of pharmaceutical companies
.
Statistics show that in 2021, a total of 38 pharmaceutical companies will be listed on the A-share Science and Technology Innovation Board, 10 more than the 28 listed in 2020
.
It can be seen that the innovation and development of the biopharmaceutical industry is active
.
It is worth mentioning that the stock prices and secondary market performance of innovative drug companies are also gradually differentiated
.
Since 2022, there have been many new pharmaceutical stocks that have been listed on the market and have broken.
For example, on January 18, Maiwei Bio has broken on the first day of listing on the Science and Technology Innovation Board, and it has fallen 29.
6% on the day
.
On January 19, Maiwei Bio’s stock price quickly rebounded by 30.
20%.
On January 20, Maiwei Bio’s opening fluctuated sharply.
As of the close, Maiwei Bio’s stock price fell by more than 14%, with a market value of 10.
95 billion yuan
.
The industry believes that the follow-up capital market may have higher investment requirements for innovative drugs, such as analyzing the clinical pipeline, product competitiveness, market space, competition pattern of the entire product, future commercialization value, and product pipeline value of innovative drug companies.
where to wait
.
Therefore, follow-up innovative drug companies need to pay attention to strengthening basic research in the process of development, breaking the homogeneity of drug research and development, and improving the commercialization ability of innovative drugs
.
The funds raised will be mainly used to promote the company's research pipeline for Parkinson's disease- - NouvNeu001 is carrying out the first phase of clinical work, and at the same time supports the company's follow-up pipeline - NS001 in the Sino-US new drug clinical research (IND) dual application
.
On the same day, Aiwei Pharmaceutical, an innovative biotechnology company focusing on the field of ophthalmic treatment, announced the completion of US$25 million in Series A+ financing.
The company plans to use the investment funds to complete the global Phase II trial of the first-line treatment drug IVIEW-1201 for viral conjunctivitis , and advance the company's preclinical programs, including new class I and class II drugs for the treatment of dry eye and cataracts, into clinical development
.
Recently, Sihuan Pharmaceutical also announced that its holding subsidiary Xuanzhu Bio has completed over 600 million yuan in Series B financing
.
Xuanzhu Bio is an innovative drug subsidiary of Sihuan Pharmaceutical, a large domestic pharmaceutical and medical beauty group.
It has the ability to independently develop innovative drugs, and has formed a complete R&D system.
It has complete drug development and industrialization capabilities, and does not rely on license in And CRO, with the ability to continue innovation and continuous output
.
Innovative biopharmaceutical companies are ushering in a capital feast
.
According to statistics from Southwest Securities, in the first half of this year, innovative drugs completed 4 large financing events of over 1 billion yuan; and 8 large financing events of over 500 million yuan, accounting for 5.
9%
.
In addition, there were 45 large-amount financing events exceeding 100 million yuan in the first half of the year, accounting for 33.
3%
.
In the financing event of more than 1 billion yuan, the domestic mRNA new drug research and development company Siwei has completed a financing amount of more than 1 billion yuan
.
From the perspective of the general background, with the advancement of the pharmaceutical reform, the pharmaceutical industry has accelerated into a new era of innovation.
Based on the complete domestic innovative drug industry chain, huge domestic demand market and huge space for overseas exports, the market prospect of innovative pharmaceutical companies is very broad.
.
In this context, capital is paying more and more attention to biomedicine, making the industry's IPO financing activities more active
.
With the help of capital, China's innovative pharmaceutical companies have also opened a new stage of development
.
In particular, the launch of the Science and Technology Innovation Board has greatly improved the inclusiveness and adaptability of technologically innovative companies, promoted new discovery of value in the pharmaceutical industry, and ushered in the intensive listing of pharmaceutical companies
.
Statistics show that in 2021, a total of 38 pharmaceutical companies will be listed on the A-share Science and Technology Innovation Board, 10 more than the 28 listed in 2020
.
It can be seen that the innovation and development of the biopharmaceutical industry is active
.
It is worth mentioning that the stock prices and secondary market performance of innovative drug companies are also gradually differentiated
.
Since 2022, there have been many new pharmaceutical stocks that have been listed on the market and have broken.
For example, on January 18, Maiwei Bio has broken on the first day of listing on the Science and Technology Innovation Board, and it has fallen 29.
6% on the day
.
On January 19, Maiwei Bio’s stock price quickly rebounded by 30.
20%.
On January 20, Maiwei Bio’s opening fluctuated sharply.
As of the close, Maiwei Bio’s stock price fell by more than 14%, with a market value of 10.
95 billion yuan
.
The industry believes that the follow-up capital market may have higher investment requirements for innovative drugs, such as analyzing the clinical pipeline, product competitiveness, market space, competition pattern of the entire product, future commercialization value, and product pipeline value of innovative drug companies.
where to wait
.
Therefore, follow-up innovative drug companies need to pay attention to strengthening basic research in the process of development, breaking the homogeneity of drug research and development, and improving the commercialization ability of innovative drugs
.
